Cargando…
Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation( )
AIMS: Patients with heart failure with reduced ejection fraction (HFrEF) are at significant risk of stroke. Anticoagulation reduces this risk in patients with and without atrial fibrillation (AF), but the risk-to-benefit balance in the latter group, overall, is not favourable. Identification of pati...
Autores principales: | Kondo, Toru, Abdul-Rahim, Azmil H, Talebi, Atefeh, Abraham, William T, Desai, Akshay S, Dickstein, Kenneth, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Packer, Milton, Petrie, Mark, Ponikowski, Piotr, Rouleau, Jean L, Sabatine, Marc S, Swedberg, Karl, Zile, Michael R, Solomon, Scott D, Jhund, Pardeep S, McMurray, John J V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637422/ https://www.ncbi.nlm.nih.gov/pubmed/36017729 http://dx.doi.org/10.1093/eurheartj/ehac487 |
Ejemplares similares
-
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
por: Curtain, James P, et al.
Publicado: (2021) -
Dapagliflozin for heart failure according to body mass index: the DELIVER trial( )
por: Adamson, Carly, et al.
Publicado: (2022) -
A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction
por: Vaduganathan, Muthiah, et al.
Publicado: (2020) -
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
por: Docherty, Kieran F, et al.
Publicado: (2020) -
Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER
por: Butt, Jawad H, et al.
Publicado: (2023)